# Cryptococcal Optimal ART Timing Trial

> **NCT01075152** · PHASE4 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 177 (actual)

## Conditions studied

- Cryptococcal Meningitis
- HIV Infections
- AIDS

## Interventions

- **DRUG:** efavirenz
- **BIOLOGICAL:** nucleoside

## Key facts

- **NCT ID:** NCT01075152
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-10
- **Final completion:** 2013-03
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01075152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01075152, "Cryptococcal Optimal ART Timing Trial". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01075152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*